AstraZeneca's Merrem Approved For Skin Infections
This article was originally published in The Pink Sheet Daily
A supplemental approval for complicated skin and skin structure infections in children and adults was based on a Phase III trial comparing meropenem to Merck's Primaxin. AstraZeneca is highlighting Merrem's action in elderly and diabetes mellitus patients.
You may also be interested in...
A possible settlement between Merck and tax authorities could be significantly smaller than GlaxoSmithKline's recent settlement with the IRS based on the companies' projected liability
Pfizer's success will depend on its ability to negotiate the paradox of increasing demand for pharmaceuticals coupled with growing attempts to restrain costs, CEO Jeffrey Kindler said
Pfizer will continue to support the insomnia product for up to six months.